JFK Jnr will be cutting 3500 jobs from the FDA. Despite assurances that reviewers will not lose their job, I cannot see how cutting all these jobs will improve review and approval times. The collateral damage of such cuts must surely cross impact even the review and approval processes.
Ann: Alterity Completes Last Patient Visit in Open-Label Trial, page-18
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.001(10.0%) |
Mkt cap ! $100.4M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.1¢ | 1.0¢ | $12.66K | 1.210M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 4352071 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 8220041 | 19 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| ATH (ASX) Chart |